E-DRUG: Independent Drug and Healthcare Newsletter for April 2019
-----------------------------------------------------------------------------------
Newsletter, April 2019
Independent Drug & Healthcare Newsletter from the non-profit journal Prescrire International
N° 203 April 2019
View the contents
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
Like what you see?
Subscribe to Prescrire International
In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW Drugs to avoid in 2019
To make it easier to choose quality care, and to prevent disproportionate harms to patients, Prescrire has published its annual update of drugs to avoid. Using a reliable, rigorous and independent methodology, Prescrire's editors identified 93 drugs currently authorised in France or the European Union that are more harmful than beneficial in all the approved indications.
Read more
--------------------------------------------------------------------------------
FREE DOWNLOAD In the April issue of Prescrire International - Drugs in 2018: a brief overview
In 2018, 99 new products or new indications were reviewed and rated in our French edition. Of the 35 that were deemed to advance patient care, 13 constituted a notable advance and 22 were rated "Possibly helpful", while 50 drugs were judged to be "nothing new".
Read more
--------------------------------------------------------------------------------
SUBSCRIBE NOW Subscribe today for full access to top-quality content from Prescrire International
Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries).
Subscribe now
--------------------------------------------------------------------------------
Prescrire's ratings of new products and indications over the past 10 years
Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.
Read more
--------------------------------------------------------------------------------
Therapeutic advances in 2018 compared with the previous 10 years
Our recap of the drugs reviewed in our French edition La revue Prescrire during the previous year includes a graphic summing up the ratings Prescrire's editors gave to new drugs and indications, compared with the previous ten years.
Read more
--------------------------------------------------------------------------------
Multiple sclerosis: wasted opportunities
The drugs on the market have been so poorly evaluated that healthcare professionals are not able to make the best use of the available treatments, to the detriment of patients.
Read more
--------------------------------------------------------------------------------
Pregnancy and lower urinary tract infection: opt for cefuroxime
Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment.
Read more
--------------------------------------------------------------------------------
ADVANCING HEALTHCARE POLICY Last chance to safeguard citizens' protections by removing "Innovation Principle" from Horizon Europe (March 2019)
A joint declaration, signed by Prescrire, calls for the immediate and complete removal of the "innovation principle" from Horizon Europe, the next EU Framework Programme for Research and Innovation, because it threatens the Precautionary Principle and is nothing more than an attempt to keep regulation of dangerous products at bay.
Read more
--------------------------------------------------------------------------------
COMING SOON Enjoy these features, and more, in our upcoming issues
Letermovir to prevent cytomegalovirus reactivation * Angiotensin II receptor antagonists, also known as "sartans": psoriasis * Oral antihistamines and pruritus associated with skin disorders * Unconjugated pneumococcal vaccine and COPD * Drugs for Alzheimer's disease: reduction in the number of prescriptions too slow...
Subscribe now
Share this with a friend or colleague: Forward this email
Prescrire International <international@prescrire.org>